Literature DB >> 3917355

Aspects of amino acid and protein metabolism in cancer-bearing states.

A M Landel, W G Hammond, M M Meguid.   

Abstract

Overt malnutrition is seen in about 40% of patients hospitalized for treatment of cancer. In patients whose primary treatment modality is surgical, morbidity and mortality is twice as high in the malnourished group as in the normally nourished patients. This clinically important malnutrition is a consequence of obligatory parasitism by the tumor, which grows at its own genetically determined rate and which competes effectively with the host for the limited available nutrients. Administration of extra nutritional support as total parenteral nutrition (TPN) can alter the tumor-host nutritional balance so that host repletion may occur. Provision of a significant proportion of TPN calories as fat diminishes the incidence of glucose intolerance and reduces the incidence of abnormal liver function. In vitro and in vivo studies both show that leucine is the significant controlling branched-chain amino acid in the TPN mixture, and adequate leucine content is a crucial component of effective TPN. Variations in TPN content of large neutral amino acids have important effects on brain tyrosine and tryptophan availability and hence may also effect neurotransmitter activity. Although the usefulness of TPN for correcting malnutrition in cancer patients is clear, the optimal choices of constituents for the TPN mixture continue to evolve.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917355     DOI: 10.1002/1097-0142(19850101)55:1+<230::aid-cncr2820551305>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Amino acid metabolism in tumour-bearing mice.

Authors:  S Rivera; J Azcón-Bieto; F J López-Soriano; M Miralpeix; J M Argilés
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

Review 2.  The metabolic environment of cancer.

Authors:  J M Argilés; J Azcón-Bieto
Journal:  Mol Cell Biochem       Date:  1988-05       Impact factor: 3.396

3.  Antiproliferative role of Indigofera aspalathoides on 20 methylcholanthrene induced fibrosarcoma in rats.

Authors:  Sivagnanam Selva Kumar; Mudiganti Ram Krishna Rao; Maruthaiveeran Periyasamy Balasubramanian
Journal:  Asian Pac J Trop Biomed       Date:  2012-12

4.  Food avoidance in patients undergoing cancer chemotherapy.

Authors:  S Holmes
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

Review 5.  Malignant disease: nutritional implications of disease and treatment.

Authors:  S Holmes; J W Dickerson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

6.  Glutamine: A novel approach to chemotherapy-induced toxicity.

Authors:  Kumar Gaurav; R K Goel; Mridula Shukla; Manoj Pandey
Journal:  Indian J Med Paediatr Oncol       Date:  2012-01

7.  Chemotherapeutic Efficacy of Indigofera aspalathoides on 20-Methylcholanthrene-Induced Fibrosarcoma in Rats.

Authors:  Selva Kumar Sivagnanam; Mudiganti Ram Krishna Rao; Maruthaiveeran Periyasamy Balasubramanian
Journal:  ISRN Pharmacol       Date:  2012-03-05

8.  Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry.

Authors:  Hu Song; Jun-Sheng Peng; Yao Dong-Sheng; Zu-Li Yang; Huan-Liang Liu; Yi-Ke Zeng; Xian-Ping Shi; Bi-Yan Lu
Journal:  Braz J Med Biol Res       Date:  2011-11-25       Impact factor: 2.590

Review 9.  Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases.

Authors:  Akram Safaei; Afsaneh Arefi Oskouie; Seyed Reza Mohebbi; Mostafa Rezaei-Tavirani; Mohammad Mahboubi; Maryam Peyvandi; Farshad Okhovatian; Mona Zamanian-Azodi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016

10.  Metabolic gene NR4A1 as a potential therapeutic target for non-smoking female non-small cell lung cancer patients.

Authors:  Rong Sun; Min-Yue Bao; Xin Long; Yuan Yuan; Miao-Miao Wu; Xin Li; Jin-Ku Bao
Journal:  Thorac Cancer       Date:  2019-02-25       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.